Mary Ann Melnick
- Pulmonary and Respiratory Medicine top 5%
- Oncology top 5%
- Molecular Biology
- Cancer Research top 10%
- Pathology and Forensic Medicine
- Co-authors
- Katerina PolitiMarc LadanyiValentina PirazzoliKen TakezawaYelena Y. JanjigianVincent A. MillerKadoaki OhashiCaroline A. Nebhan
- Topics
- Lung Cancer Treatments and Mutations (12 papers)Colorectal Cancer Treatments and Studies (5 papers)HER2/EGFR in Cancer Research (3 papers)
- Partner nations
- United StatesJapanNetherlands
In The Last Decade
Mary Ann Melnick
14 papers receiving 970 citations
Hit Papers
Peers
Comparison fields: 5 of 55
- Pulmonary and Respiratory Medicine 676
- Oncology 586
- Molecular Biology 491
- Cancer Research 261
- Pathology and Forensic Medicine 89
Countries citing papers authored by Mary Ann Melnick
This map shows the geographic impact of Mary Ann Melnick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Ann Melnick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Ann Melnick more than expected).
Fields of papers citing papers by Mary Ann Melnick
This network shows the impact of papers produced by Mary Ann Melnick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Ann Melnick. The network helps show where Mary Ann Melnick may publish in the future.
Co-authorship network of co-authors of Mary Ann Melnick
This figure shows the co-authorship network connecting the top 25 collaborators of Mary Ann Melnick. A scholar is included among the top collaborators of Mary Ann Melnick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Ann Melnick. Mary Ann Melnick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 18 | |
| 2 | 31 | |
| 3 | 52 | |
| 4 | 6 | |
| 5 | 57 | |
| 6 | 4 | |
| 7 | 5 | |
| 8 | 1 | |
| 9 | 26 | |
| 10 | 1 | |
| 11 | 12 | |
| 12 | 55 | |
| 13 | 154 | |
| 14 | HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutationbreakdown → | 555 |
About Mary Ann Melnick
Mary Ann Melnick is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 14 papers that have together received 977 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (3 papers). The work is most often cited by research in Oncology (586 citations), Pulmonary and Respiratory Medicine (676 citations) and Cancer Research (261 citations). Mary Ann Melnick has collaborated with scholars based in United States, Japan and Netherlands. Frequent co-authors include Katerina Politi, Marc Ladanyi, Valentina Pirazzoli, Ken Takezawa, Yelena Y. Janjigian, Vincent A. Miller, Kadoaki Ohashi, Caroline A. Nebhan, Paula J. Spitzler and Mark G. Kris. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.